[go: up one dir, main page]

WO2006010620A3 - Olanzapine salts and their conversion to olanzapine free base - Google Patents

Olanzapine salts and their conversion to olanzapine free base Download PDF

Info

Publication number
WO2006010620A3
WO2006010620A3 PCT/EP2005/008218 EP2005008218W WO2006010620A3 WO 2006010620 A3 WO2006010620 A3 WO 2006010620A3 EP 2005008218 W EP2005008218 W EP 2005008218W WO 2006010620 A3 WO2006010620 A3 WO 2006010620A3
Authority
WO
WIPO (PCT)
Prior art keywords
olanzapine
salts
conversion
free base
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/008218
Other languages
French (fr)
Other versions
WO2006010620A2 (en
Inventor
Igor Simonic
Roman Lenarsic
Berta Kotar-Jordan
Rok Zupet
Joze Gnidovec
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KRKA dd
Original Assignee
KRKA Tovarna Zdravil dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KRKA Tovarna Zdravil dd filed Critical KRKA Tovarna Zdravil dd
Priority to EP05779020A priority Critical patent/EP1781665A2/en
Publication of WO2006010620A2 publication Critical patent/WO2006010620A2/en
Publication of WO2006010620A3 publication Critical patent/WO2006010620A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides salts olanzapine useful as intermediates in the isolation of olanzapine from complex reaction mixtures. These salts can be used for the production of olanzapine base which has a suitable purity for pharmaceutical use and can easily be converted to anhydrous olanzapine polymorphic form I, in high yields.
PCT/EP2005/008218 2004-07-28 2005-07-28 Olanzapine salts and their conversion to olanzapine free base Ceased WO2006010620A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05779020A EP1781665A2 (en) 2004-07-28 2005-07-28 Olanzapine salts and their conversion to olanzapine free base

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200400219A SI21850A (en) 2004-07-28 2004-07-28 Salts of olanzapin and their transformation into free base of olanzapin
SIP-200400219 2004-07-28

Publications (2)

Publication Number Publication Date
WO2006010620A2 WO2006010620A2 (en) 2006-02-02
WO2006010620A3 true WO2006010620A3 (en) 2006-06-08

Family

ID=35448338

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008218 Ceased WO2006010620A2 (en) 2004-07-28 2005-07-28 Olanzapine salts and their conversion to olanzapine free base

Country Status (3)

Country Link
EP (1) EP1781665A2 (en)
SI (1) SI21850A (en)
WO (1) WO2006010620A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058773A1 (en) 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
PL377084A1 (en) * 2005-09-15 2007-03-19 Koźluk Tomasz Nobilus Ent New olanzapine compounds and method for their manufacture
US8106188B2 (en) 2006-06-01 2012-01-31 Aurobindo Pharma Ltd Process for preparing olanzapine form I
PT2081921E (en) * 2006-07-10 2010-12-10 Paion Uk Ltd Short-acting benzodiazepine salts and their polymorphic forms
GB0613693D0 (en) 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
PL381564A1 (en) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent The manner of production of basically clean variety of polymorphic olanzapine
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (en) 2013-03-04 2015-09-09 Ono Pharmaceutical Co EXCELLENT OXIDATION REACTION IN THE CONVERSION INDEX
CA3177848A1 (en) * 2020-05-05 2021-11-11 Guochuan Emil Tsai Salts of neuroceuticals and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454436A1 (en) * 1990-04-25 1991-10-30 Lilly Industries Limited Pharmaceutical compounds
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
WO2003055438A2 (en) * 2001-12-24 2003-07-10 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
WO2003101997A1 (en) * 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
WO2004094433A1 (en) * 2003-04-22 2004-11-04 EGIS Gyógyszergyár Rt. New polymorphs of olanzapine hydrochloride
WO2005070937A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. A process for making olanzapine in a polymorph form i

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454436A1 (en) * 1990-04-25 1991-10-30 Lilly Industries Limited Pharmaceutical compounds
US5637584A (en) * 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
WO2003055438A2 (en) * 2001-12-24 2003-07-10 Sun Pharmaceutical Industries Limited Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
WO2003101997A1 (en) * 2002-05-31 2003-12-11 Geneva Pharmaceuticals, Inc. Process of preparation of olanzapine form i
WO2004094433A1 (en) * 2003-04-22 2004-11-04 EGIS Gyógyszergyár Rt. New polymorphs of olanzapine hydrochloride
WO2005070937A1 (en) * 2004-01-27 2005-08-04 Synthon B.V. A process for making olanzapine in a polymorph form i

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OERTHER, S.; AHLENIUS, S.: "Atypical antipsychotics and dopamine D1 receptor agonism: an in vivo experimental study using core temperature measurements in the rat", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 292, no. 2, 2000, pages 731 - 736, XP002359329 *
See also references of EP1781665A2 *

Also Published As

Publication number Publication date
EP1781665A2 (en) 2007-05-09
WO2006010620A2 (en) 2006-02-02
SI21850A (en) 2006-02-28

Similar Documents

Publication Publication Date Title
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
WO2009102155A3 (en) Process for preparation of 2-methyl-2´-phenylpropionic acid derivatives and novel intermediate compounds
TW200616646A (en) Synthesis of boronic ester and acid compounds
IL190551A0 (en) Novel process for the preparation of acid chlorides
ZA200709926B (en) Process for the conversion of synthesis gas to oxygenates
NZ715101A (en) Method for producing methyl-{ 4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate and its purification for use thereof as pharmaceutical substance
WO2006021454A3 (en) Pyrimidine derivatives
EP1807604A4 (en) Production of free gas by gas hydrate conversion
WO2012004396A3 (en) Process of preparing a thrombin specific inhibitor
IL183591A0 (en) Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives
WO2006021457A3 (en) Pyrimidine derivatives
WO2009134531A3 (en) Total synthesis of salinosporamide a and analogs thereof
WO2006071130A8 (en) A process for preparation of imatinib base
MY146671A (en) Tetrahydronaphthaline derivatives, methods for the production and use thereof as anti-inflammatory agents
DK1670778T3 (en) Rearranged pentanols, a process for their preparation and their use as anti-inflammatory
WO2006010620A3 (en) Olanzapine salts and their conversion to olanzapine free base
WO2008021346A3 (en) Pure paliperidone and processes for preparing thereof
MX2013000294A (en) Intermediates and process for preparing a thrombin specific inhibitor.
WO2011157388A8 (en) Process for the preparation of pteridine derivatives
HU0402466D0 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
WO2012026897A9 (en) A process for the preparation of imatinib base
WO2009116072A3 (en) Process for preparation of pyridinylmethylsulphinyl benzimidazole compounds and pyridine intermediates
WO2014133291A9 (en) Method for preparing (2rs)-amino-(3s)-hydroxy-butyric acid or derivative thereof
WO2006122020A3 (en) Process for production of 4-biphenylyazetidin-2-ones
WO2009130710A3 (en) A process for the preparation of paliperidone intermediates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005779020

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005779020

Country of ref document: EP